QSAM Biosciences Signs Term Sheet to be Acquired by Telix Pharmaceuticals; Receives $2 Million Pre-Closing Collaboration and Option Fee
November 14, 2023 07:30 ET
|
QSAM Biosciences Inc.
Austin, TX, Nov. 14, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing therapeutic radiopharmaceuticals for the treatment of primary and secondary bone cancer and...
QSAM Biosciences Provides Update to Shareholders on Phase 1 Progress and Preliminary Clinical Data
August 16, 2023 08:00 ET
|
QSAM Biosciences Inc.
AUSTIN, Texas, Aug. 16, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
Global Interventional Oncology Devices Market Report 2023: Players Include Boston Scientific, Medtronic, Terumo, and Philips Volcano
March 30, 2023 10:18 ET
|
Research and Markets
Dublin, March 30, 2023 (GLOBE NEWSWIRE) -- The "Interventional Oncology Devices Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. This report provides...
Artificial Tendons and Ligaments Market Is Expected to Reach $165.7 Million by 2031: Says AMR
December 14, 2022 03:59 ET
|
Allied Market Research
Portland, OR, Dec. 14, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global Artificial Tendons And Ligaments Market was estimated at $64.3 million in 2021...
QSAM Biosciences Adds Rutgers Cancer Institute of New Jersey as Clinical Trial Site To Expand and Advance Study of CycloSam® in the Treatment of Bone Cancer
October 26, 2022 08:00 ET
|
QSAM Biosciences Inc.
Austin, TX, Oct. 26, 2022 (GLOBE NEWSWIRE) -- QSAM Biosciences, Inc. (OTCQB: QSAM), a company developing next generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
Global Bone Cancer Treatment Market to Reach $1.8 Billion by 2031: Says AMR
October 21, 2022 08:51 ET
|
Allied Market Research
Portland, OR, Oct. 21, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global Bone Cancer Treatment Market was estimated at $1.2 billion in 2021 and is...
QSAM Biosciences Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 16, 2022 08:00 ET
|
QSAM Biosciences Inc.
Progress Shown in Phase 1 Clinical Program Evaluating CycloSam® Radiopharmaceutical Drug Candidate for Treatment of Metastatic Bone Cancer AUSTIN, Texas, Aug. 16, 2022 (GLOBE NEWSWIRE) -- QSAM...
Hospital at Home Program Helping Cancer Patients and Their Families With Medical and Financial Support Services
June 29, 2022 16:00 ET
|
Hospital At Home
CALGARY, Alberta, June 29, 2022 (GLOBE NEWSWIRE) -- As a competitive dancer and avid horseback rider, Lauren Gamble's life changed completely on Aug. 13, 2021. Lauren received an osteosarcoma...
QSAM Biosciences Activates Clinical Sites and Opens Enrollment for its Phase 1 Clinical Trial of CycloSam® for the Treatment of Bone Cancer
December 01, 2021 09:00 ET
|
QSAM Biosciences Inc.
Austin, TX, Dec. 01, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
Global $3.32 Bn Interventional Oncology Devices Market to 2030: Embolization Devices, Ablation Devices, & Support Devices
July 16, 2021 05:53 ET
|
Research and Markets
Dublin, July 16, 2021 (GLOBE NEWSWIRE) -- The "Interventional Oncology Devices Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's...